The global Anacetrapib market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.   Anacetrapib is a CETP inhibitor being developed to treat hypercholesterolemia and prevent cardiovascular disease. Download FREE Sample...